In Depth 30 Apr 2025
The future of NSCLC treatment: what’s in store for the therapeutic space?
Here we delve into the different kinds of NSCLC therapies in the running to potentially address late-stage cancer that is often difficult to treat.
Cancer
- Latest Posts
News and Trends 2 Apr 2025
Top biotech deals of March 2025
Learn about the top biotech deals of March 2025. Small molecules, bispecific antibodies, and protein therapies were all part of major collaborations.
In Depth 26 Mar 2025
A guide to kinase inhibitors in biotech: From cancer breakthroughs to autoimmune innovations
Delve into the kinase inhibitors’ diverse landscape, from cancer breakthroughs to autoimmune disease innovations.
News and Trends 24 Mar 2025
First-ever RIPTAC enters clinic: all you need to know about this new cancer approach
The first RIPTAC has just hit the clinic. Learn about this new technology that is being developed by Halda Therapeutics.
Best in Biotech 18 Mar 2025
Cancer vaccines: 11 biotechs to keep an eye out for
As various biotechs across the world specialize in the production of cancer vaccines, here are 11 companies making progress in the field.
Best in Biotech 13 Mar 2025
Nine biotechs thriving in Seattle in 2025
In this article, let us take a look at some of the major biotech companies in Seattle that are contributing to the biotech industry at large.
ADVERTISEMENT
ADVERTISEMENT
In Depth 12 Mar 2025
Checkpoint inhibitors in cancer: breakthroughs, setbacks, and what’s next
Checkpoint inhibitors are drugs that harness the immune system to destroy cancer cells. Let us review what’s been going on in the field.
Best in Biotech 25 Feb 2025
Seven biotech spinouts to watch out for in 2025
Here are seven biotech spinouts to keep an eye out for this year that specialize in a number of therapeutic areas.
News and Trends 24 Feb 2025
Over $3 billion in a month: Why is Eli Lilly starting 2025 on a buying spree?
This year has seen Eli Lilly sign several licensing deals to bolster its position across a range of therapeutic areas amid growing drug revenues.
In Depth 18 Feb 2025
T cell engagers: A promising, fast-growing field for cancer and autoimmune disease treatments
T cell engagers represent a novel approach to tuning the immune system to target and kill tumor cells, expanding treatment options for cancer.
Podcast 14 Feb 2025
Reversing cancer mechanisms to fight back against solid tumors
This week, we have a conversation with Catalym’s Eugen Leo about Visugromab is a monoclonal antibody that neutralizes the tumor-derived growth differentiation factor-15.
In Depth 4 Feb 2025
World Cancer Day: trends in cancer therapeutics to look forward to in 2025
As we observe World Cancer Day today, let us look at some of the trends in cancer therapeutics expected to improve cancer care in 2025.
ADVERTISEMENT
